胸腺肽联合参麦辅助治疗慢性阻塞性肺病急性加重期的疗效及安全性

Efficacy and Safety of Thymic Peptide Assisted with Shenmai Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的分析胸腺肽联合参麦辅助治疗慢性阻塞性肺病急性加重期的疗效及安全性。方法整群选取该院2014年1月—2015年6月收治的100例慢性阻塞性肺病急性加重期患者,随机分为两组。常规组患者接受胸腺肽治疗,干预组患者在此基础上辅以参麦治疗。观察两组氧气分压、二氧化碳分压和肺功能。结果治疗后所有患者氧气分压和二氧化碳分压均改善,且干预组改善水平显著优于常规组(P<0.05);治疗后所有患者肺功能指标均较治疗前提高,且干预组FEV1、FVC、VC、PEF指标水平显著高于常规组(P<0.05)。两组安全性相似(P>0.05)。结论胸腺肽联合参麦治疗慢性阻塞性肺病急性加重期效果确切。

Objective To analyze the curative effect and safety of thymic peptide assisted with shenmai injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods 100 patients suffering from acute exac-erbation of chronic obstructive pulmonary disease from January 2014 and June 2015 were randomly divided into two groups. Patients in the conventional group were treated with thymic peptide, while those in the intervention group were treated with thymic peptide assisted with shenmai injection. The oxygen partial pressure, carbon dioxide partial pressure and pulmonary function of the two groups were observed. Results After treatment, all the patients got improvement in terms of oxygen par-tial pressure, carbon dioxide partial pressure, and the improvement of the intervention group was better than that in the con-ventional group,（P〈0.05）;all the patients got improvement in pulmonary function after treatment, what＇s more, the indicators including FEV1, FVC, VC, PEF were all higher in the intervention group than in the conventional group,（P〈0.05）. No statis-tically significant difference can be found in safety of the treatment between the two groups, （P〉0.05）. Conclusion The cu-rative effect of thymic peptide assisted with shenmai injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease is evident.